VistaGenVistaGen and Capsant have signed a strategic commercialization agreement under which the companies will combine their leading-edge stem cell biology and 3D cell culture platforms, respectively, to advance their mutual business interests worldwide.

The new collaboration will focus on late-stage development and commercialization of a new generation of human stem cell-based biological tools enabling Clinical Trials in a Test Tube and increased R&D productivity in the pharmaceutical industry.

VistaGen is among the world's leading biotechnology companies focused on commercializing the power of stem cell technologies to transform the ways new drugs are discovered and tested. Capsant's OrganDot 3D technology is a novel high-throughput, in-vitro drug testing platform using stem cell-based 3D "micro-organ" tissue cultures.

Dr. Ralph Snodgrass, VistaGen CEO, said, "Capsant's world class OrganDot 3D technology significantly expands our ability to deliver a valuable synergistic combination of leading stem cell biology, 3D tissue culture and electrophysiological technologies, and a multi-dimensional automated knowledgebase through our Clinical Trials in a Test Tube platform. Together, we can now provide our partners with the industry's most reproducible, mature, and functional human cells that grow as 3D 'micro-organs' in a commercially scalable platform with integrated analytical capabilities. This new agreement advances our common goal of providing new-generation drug development tools that are a vital necessity to improve drug R&D productivity in the pharmaceutical industry."

Riccardo Pigliucci, Capsant executive chairman, said, "After a comprehensive global evaluation of stem cell technologies, our scientific team easily concluded that VistaGen's stem cell differentiation technologies are the best at producing functional human cells, reproducibly, and at the scale needed to optimize the commercial potential of our advanced 3D micro-organ culture systems, thus allowing us to deliver truly innovative applications for drug development and personalized medicine. We look forward to a rapidly expanding long-term business relationship with VistaGen."